Literature DB >> 27330009

Pioglitazone seems safe and effective for patients with fatty liver disease and diabetes.

Jacqui Wise1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27330009     DOI： 10.1136/bmj.i3435

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  2 in total

Review 1.  GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis.

Authors:  Shahla Rezaei; Reza Tabrizi; Peyman Nowrouzi-Sohrabi; Mohammad Jalali; Stephen L Atkin; Khalid Al-Rasadi; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Can J Gastroenterol Hepatol       Date:  2021-11-12

Review 2.  Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.

Authors:  Maryam Mahjoubin-Tehran; Antonio De Vincentis; Dimitri P Mikhailidis; Stephen L Atkin; Christos S Mantzoros; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Mol Metab       Date:  2020-07-13       Impact factor: 7.422
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.